

Supplementary Material to: Bin WJJ, Chow A, Smith HE, et al. Demographic diversity of participants in clinical trials conducted in Singapore. *Ann Acad Med Singap* 2024;53:446-54.
DOI: <https://doi.org/10.47102/annals-acadmedsg.2023252>

Appendix S1. Search strategies.

PubMed search strategy

Search no.	Query	Sort by	Filter	Search detail	Result
9	#7 AND #3		2017-2022	((("Singapore"[MeSH Terms] OR "Singapore"[Title/Abstract]) AND (("randomized controlled trials as topic"[MeSH Terms] OR "RCT"[All Fields] OR (("ambulatory care facilities"[MeSH Terms] OR ("ambulatory"[All Fields] AND "care"[All Fields] AND "facilities"[All Fields]) OR "ambulatory care facilities"[All Fields] OR "clinic"[All Fields] OR "clinic s"[All Fields] OR "clinical"[All Fields] OR "clinically"[All Fields] OR "clinicals"[All Fields] OR "clinics"[All Fields]) AND "trial*"[All Fields]) OR ("Controlled"[All Fields] AND "trial*"[All Fields])) AND ("pharmaceutical preparations"[MeSH Terms] OR "drug*"[All Fields] OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutic"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutic preparations"[All Fields]) OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutical"[All Fields] AND "preparation"[All Fields]) OR "pharmaceutical preparation"[All Fields])))) AND (2017:2022[pdat])	174

8	#7 AND #3		("Singapore"[MeSH Terms] OR "Singapore"[Title/Abstract]) AND (("randomized controlled trials as topic"[MeSH Terms] OR "RCT"[All Fields] OR (("ambulatory care facilities"[MeSH Terms] OR ("ambulatory"[All Fields] AND "care"[All Fields] AND "facilities"[All Fields]) OR "ambulatory care facilities"[All Fields] OR "clinic"[All Fields] OR "clinic s"[All Fields] OR "clinical"[All Fields] OR "clinically"[All Fields] OR "clinicals"[All Fields] OR "clinics"[All Fields]) AND "trial*"[All Fields]) OR ("Controlled"[All Fields] AND "trial*"[All Fields])) AND ("pharmaceutical preparations"[MeSH Terms] OR "drug*"[All Fields] OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutic"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutic preparations"[All Fields]) OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutical"[All Fields] AND "preparation"[All Fields]) OR "pharmaceutical preparation"[All Fields]))))	478
---	-----------	--	--	-----

7	#4 AND #5		("randomized controlled trials as topic"[MeSH Terms] OR "RCT"[All Fields] OR ("ambulatory care facilities"[MeSH Terms] OR ("ambulatory"[All Fields] AND "care"[All Fields] AND "facilities"[All Fields]) OR "ambulatory care facilities"[All Fields] OR "clinic"[All Fields] OR "clinic s"[All Fields] OR "clinical"[All Fields] OR "clinically"[All Fields] OR "clinicals"[All Fields] OR "clinics"[All Fields]) AND "trial*"[All Fields]) OR ("Controlled"[All Fields] AND "trial*"[All Fields])) AND ("pharmaceutical preparations"[MeSH Terms] OR "drug*"[All Fields] OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutic"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutic preparations"[All Fields]) OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutical"[All Fields] AND "preparation"[All Fields]) OR "pharmaceutical preparation"[All Fields]))	834,383
5	pharmaceutical preparations[MeSH Terms] OR drug* OR Pharmaceutic Preparations OR Pharmaceutical Preparation		"pharmaceutical preparations"[MeSH Terms] OR "drug*"[All Fields] OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutic"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutic preparations"[All Fields]) OR ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR ("pharmaceutical"[All Fields] AND "preparation"[All Fields]) OR "pharmaceutical preparation"[All Fields])	6,893,190

4	Randomized Controlled Trial[MeSH Terms] OR RCT OR Clinical Trial* OR Controlled Trial*		"randomized controlled trials as topic"[MeSH Terms] OR "RCT"[All Fields] OR (("ambulatory care facilities"[MeSH Terms] OR ("ambulatory"[All Fields] AND "care"[All Fields] AND "facilities"[All Fields]) OR "ambulatory care facilities"[All Fields] OR "clinic"[All Fields] OR "clinic s"[All Fields] OR "clinical"[All Fields] OR "clinically"[All Fields] OR "clinicals"[All Fields] OR "clinics"[All Fields]) AND "trial*"[All Fields]) OR ("Controlled"[All Fields] AND "trial*"[All Fields])	1,753,718
3	#1 OR #2		"Singapore"[MeSH Terms] OR "Singapore"[Title/Abstract]	22,643
2	Singapore[Title/Abstract]		"Singapore"[Title/Abstract]	18,494
1	singapore[MeSH Terms]		"singapore"[MeSH Terms]	15,187

Embase search strategy

No.	Search	Result	Type
1	exp Singapore	25,885	Advanced
2	Signapore.ti,ab.	27,152	Advanced
3	1 or 2	33,364	Advanced
4	exp randomized controlled trial/	723,240	Advanced
5	(RCT or Clinical Trial* or Controlled Trial*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	2,368,286	Advanced
6	pharmaceutical preparations.mp.	4924	Advanced

7	(drug* or Pharmaceutical Preparations or Pharmaceutical Preparation).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	12,352,275	Advanced
8	4 or 5	2,368,802	Advanced
9	6 or 7	12,352,275	Advanced
10	8 and 9	1,496,929	Advanced
11	3 and 10	1170	Advanced
12	limit 11 to yr="2017 - 2022"	469	Advanced

Cochrane library search strategy

No.	Search	Type	Hits
1	MeSH descriptor: [Singapore] explode all trees	MeSH	355
2	Singapore:ti,ab	Limits	1413
3	#1 or #2	Limits	1570
4	MeSH descriptor: [Randomized Controlled Trial] explode all trees	MeSH	118
5	RCT or Clinical Trial* or Controlled Trial*	Limits	1,908,981
6	#4 or #5	Limits	1,908,981
7	MeSH descriptor: [Pharmaceutical Preparations] explode all trees	MeSH	76,541

8	drug* or Pharmaceutic Preparations or Pharmaceutical Preparation	Limits	683,376
9	#7 or #8	Limits	696,363
10	#6 and #9	Limits	696,218
11	#10 and #3 <i>with Publication Year from 2017 to 2022, with Cochrane Library publication date from Jan 2017 to Dec 2022, in Trials</i>	Limits	241

Web of Science search strategy

No.	Search	Hits
6	#1 AND #4, 2017-2022	48
5	#1 AND #4	112
4	#2 AND #3	206,952
3	TS=(pharmaceutical preparations or drug* or Pharmaceutic Preparations or Pharmaceutical Preparation)	2,144,836
2	TS=(randomized controlled trials or RCT or Clinical Trial* or Controlled Trial)	1,267,894
1	TS=(Singapore)	45,727

Appendix S2. Data extraction form.

1	Reference of article		
2	Year published		
3	Field of study		
4	Regions involved		
5	Conflict of interest declared as stated in the publication (Yes conflict/No conflict/No comment)		
6	Funding statement (Yes/No)		
7	Aim/Research question of randomised controlled trial (NB: as verbatim as possible)		
8	Study design (NB: include verbatim description)		
9	Recruitment strategy (e.g. Were patients hospitalised? Tertiary hospitals?)		
10	Inclusion criteria		
11	Exclusion criteria		
12	Participants	No. of participants screened/enrolled	
13		No. of participants included/randomised	
14		No. of participants excluded	
15		No. of participants (outcome/analysed)	
16		Comments	
17	Overall (BASELINE) if Singapore population described	No. of included participants from Singapore	
18		Age	
19		Sex	Male
20			Female
21		Ethnicity	Chinese
22			Malay
23			Indians
24			Others
25		No. of included participants from Singapore	

26	Treatment arm (BASELINE) if Singapore population described	Age	
27		Sex	Male
28			Female
29		Ethnicity	Chinese
30			Malay
31			Indians
32			Others
33	Control Arm (BASELINE) if Singapore population described	No. of included participants from Singapore	
34		Age	
35		Sex	Male
36			Female
37		Ethnicity	Chinese
38			Malay
39			Indians
40			Others
41	Overall (BASELINE) if Singapore population not described	No. of included participants	
42		Age	
43		Sex	Male
44			Female
45		Ethnicity	Asian
46			Non-Asian
47	Treatment arm (BASELINE) if Singapore population not described	No. of included participants	
48		Age	
49		Sex	Male
50			Female
51		Ethnicity	Asian
52			Non-Asian

53	Control Arm (BASELINE) if Singapore population not described	No. of included participants	
54		Age	
55		Sex	Male
56			Female
57		Ethnicity	Asian
58			Non-Asian
59	Comments about representativeness of sample by authors (NB: include verbatim description)		
60	Comments		
61	Did COVID affect recruitment/trial?		

Appendix S3. References of studies included.

1. Holland TL, Ginde AA, Paredes R, et al. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. *Lancet Respir Med* 2022;10:972-84.
2. Chen CLH, Nguyen TH, Marasigan S, et al. NEUROaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo-controlled randomized trial. *Alzheimers Dement (N Y)* 2021;7:e12161.
3. Dalan R, Goh LL, Lim CJ, et al. Impact of Vitamin E supplementation on vascular function in haptoglobin genotype stratified diabetes patients (EVAS Trial): a randomised controlled trial. *Nutr Diabetes* 2020;10:13.
4. Glass GF Jr, Goh CCK, Cheong RQ, et al. Effectiveness of skin cleanser and protectant regimen on incontinence-associated dermatitis outcomes in acute care patients: A cluster randomised trial. *Int Wound J* 2021;18:862-73.
5. Goh CL, Chuah SY, Derm D, et al. Double-blind, placebo-controlled trial to evaluate the effectiveness of polypodium leucotomos extract in the treatment of Melasma in Asian Skin: A pilot study. *J Clin Aesthet Dermatol* 2018;11:14-9.
6. Guo S, Manning V, Yang Y, et al. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. *J Subst Abuse Treat* 2018;91:1-11.
7. Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2021;9:1365-76.
8. Kalimuddin S, Chan YFZ, Phillips R, et al. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study. *Trials* 2018;19:305.

9. Khoo J, Hsiang J, Taneja R, et al. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. *Diabetes Obes Metab* 2017;19:1814-7.
10. Khoo J, Hsiang JC, Taneja R, et al. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. *Liver Int* 2019;39:941-9.
11. Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 2017;18:1360-72.
12. Law YXT, Tai BC, Tan YQ, et al. A Small Group Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Daily Pentoxifylline in the Management of Patients With Erectile Dysfunction with Suboptimal Treatment Response to Sildenafil. *Sex Med* 2020;8:14-20.
13. Lee WK, Iida T, Ogura Y, et al. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. *JAMA Ophthalmol* 2018;136:786-93.
14. Li J, Xu R, Qin S, et al. Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: A randomized Phase III study. *Future Oncol* 2018;14:2031-44.
15. Lim SG, Yang WL, Ngu JH, et al. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: the SWAP RCT. *Clin Gastroenterol and Hepatol* 2022;20:e228-e50.

16. Lim SL, Gandhi M, Woo KL, et al. Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proof-of-concept study. *ESC Heart Failure* 2020;7:4267-76.
17. Miow QH, Vallejo AF, Wang Y, et al. Doxycycline host-directed therapy in human pulmonary tuberculosis. *J Clin Invest* 2021;131:e141895.
18. Molton JS, Chan M, Kalimuddin S, et al. Oral vs Intravenous Antibiotics for Patients With *Klebsiella pneumoniae* Liver Abscess: a Randomized, Controlled Noninferiority Study. *Clin Infect Dis* 2020;71:952-9.
19. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet* 2020;396:1895-904.
20. Poulou V, Koh J, Ren TT, et al. A randomized pilot study of parenteral glutamine supplementation in severe sepsis. *Crit Care and Shock* 2017;20:61-7.
21. Seet RCS, Quek AML, Ooi DSQ, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial. *Int J Infect Dis* 2021;106:314-22.
22. Seneviratne CJ, Balan P, Ko KKK, et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. *Infection* 2021;49:305-11.
23. Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. *Lancet* 2019;394:1807-15.
24. Sng BL, Du W, Lee MX, et al. Comparison of double intravenous vasopressor automated system using nexfin versus manual vasopressor bolus administration for maintenance of haemodynamic stability during spinal anaesthesia for caesarean delivery: A randomised double-blind controlled trial. *Eur J Anaesthesiol* 2018;35:390-7.

25. Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. *J Clin Oncol* 2018;36:1389-95.
26. Tricou V, Low JG, Oh HM, et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial. *Vaccine* 2020;38:1513-9.
27. Wei L, Wang G, Alami NN, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). *Lancet Gastroenterol Hepatol* 2020;5:839-49.
28. Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. *Lancet Respir Med* 2022;10:888-99.
29. Wu YL, Lu S, Cheng Y, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: checkMate 078 Randomized Phase III Clinical Trial. *J Thorac Oncol* 2019;14:867-75.
30. Yap YS, Kwok LL, Syn N, et al. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: a Randomized Clinical Trial. *JAMA Oncol* 2017;3:1538-45.
31. Yeo TJ, Yeo PSD, Hadi FA, et al. Single-dose intravenous iron in Southeast Asian heart failure patients: a pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). *ESC Heart Fail* 2018;5:344-53.
32. Yuen MF, Gane EJ, Kim DJ, et al. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. *Gastroenterology* 2019;156:1392-403.e7.

33. Yuen MF, Zhou X, Gane E, et al. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. *Lancet Gastroenterol Hepatol* 2021;6:723-32.